ArticleBlood2010
The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The Potential Roles of Dietary Anthocyanins in Inhibiting Vascular Endothelial Cell Senescence and Preventing Cardiovascular Diseases.Nutrients · 2022Pooled it
- The role of lactate metabolism and lactylation in pulmonary arterial hypertension.Respiratory research · 2025Review
- Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.International journal of molecular sciences · 2024Review
- Methemoglobinemia in the Setting of G6PD Deficiency and SARS-CoV-2 Infection.Journal of community hospital internal medicine perspectives · 2023Article
- Effects of nitrite and far-red light on coagulation.Nitric oxide : biology and chemistry · 2021Article
- Endothelial cell infection and dysfunction, immune activation in severe COVID-19.Theranostics · 2021Article
- Focused Update on Pulmonary Hypertension in Children-Selected Topics of Interest for the Adult Cardiologist.Medicina (Kaunas, Lithuania) · 2020Review
- Prognostic significance of red cell distribution width and its relation to increased pulmonary pressure and inflammation in acute heart failure.Cardiology journal · 2020Article
- Versatile cell ablation tools and their applications to study loss of cell functions.Cellular and molecular life sciences : CMLS · 2019Review
- Regulation of vascular tone homeostasis by NO and HBiochemical pharmacology · 2018Review
- New cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension.PloS one · 2018Article
- Potential therapeutic action of nitrite in sickle cell disease.Redox biology · 2017Article
- The potential adverse effects of haemolysis.Blood transfusion = Trasfusione del sangue · 2017Review
- Intravascular hemolysis and the pathophysiology of sickle cell disease.The Journal of clinical investigation · 2017Review
- Hematological disorders and pulmonary hypertension.World journal of cardiology · 2016Review
- Rapid conditional targeted ablation model for hemolytic anemia in the rat.Physiological genomics · 2016Article
- Hemolysate-mediated platelet aggregation: an additional risk mechanism contributing to thrombosis of continuous flow ventricular assist devices.Perfusion · 2016Article
- Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.The Journal of clinical investigation · 2016Article
- Minireview: Genetic basis of heterogeneity and severity in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is suspected to be a strong mortality determinant of hemolytic disorders. However, direct contribution of acute intravascular hemolysis to fatal PAH has not been investigated. The roles of nitric oxide (NO) insufficiency and platelet activation in hemolysis-associated fatal PAH have been suspected but not been experimentally studied. We recently generated a unique intravascular hemolysis mouse model in which the membrane toxin, intermedilysin (ILY), exclusively lyses the erythrocytes of transgenically expressing human CD59 mice (ThCD59(RBC)), thereby inducing ILY-dose-dependent massive hemolysis. Using this murine hemolysis model, we found that the acute increase in pulmonary arterial pressure leading to right ventricle failure caused sudden death. Reduced NO bioavailability and massive platelet activation/aggregation leading to the formation of massive thrombosis specifically in the pulmonary microvasculature played the critical roles in pathogenesis of acute hemolysis-associated fatal PAH. Therapeutic interventions enhancing NO bioactivity or inhibiting platelet activation prevented sudden death or prolonged survival time via the suppression of the acute increase in pulmonary arterial pressure and improvement of right ventricle function. These findings further highlight the importance of the inhibition of platelet activation and the enhancement of NO bioavailability for the treatment and prevention of hemolysis-associated (fatal) PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.